DrugPatentWatch Database Preview
MORPHABOND ER Drug Profile
see a sample report or, see our see our flat-rate plans
When do Morphabond Er patents expire, and when can generic versions of Morphabond Er launch?
This drug has nineteen patent family members in eight countries.
The generic ingredient in MORPHABOND ER is morphine sulfate. There are twenty-three drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
Summary for MORPHABOND ER
| International Patents: | 19 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 20 |
| Patent Applications: | 2,583 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | MORPHABOND ER at DailyMed |
Pharmacology for MORPHABOND ER
| Drug Class | Opioid Agonist |
| Mechanism of Action | Full Opioid Agonists |
Medical Subject Heading (MeSH) Categories for MORPHABOND ER
Synonyms for MORPHABOND ER
| (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;sulfuric acid;pentahydrate |
| (5alpha,6alpha)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol, hydrogen sulfate (2:1) |
| 1095-53-0 |
| 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6-diol sulfate (2:1) |
| 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6-diol sulfate (2:1) pentahydrate |
| 178935-96-1 |
| 4,5-alpha-Epoxy-17-methylmorphinan-3,5-alpha-diol sulfate hydrate (2:1:5) |
| 57-27-2 (Parent) |
| 6211-15-0 |
| 64-31-3 |
| 66591-53-5 |
| 7,8-Didehydro-4,5alpha-epoxy-17-methylmorphinan-3,6alpha-diol sulfate (2:1) (salt) pentahydrate |
| 92004-19-8 |
| Apomorphine impurity B (morphine sulfate), European Pharmacopoeia (EP) Reference Standard |
| Arymo ER |
| Astramor PH (TN) |
| Astramorph |
| Astramorph PF |
| Avinza |
| Avinza (TN) |
| CAS-6211-15-0 |
| CHEBI:50731 |
| CHEBI:7003 |
| CHEMBL2096625 |
| CHEMBL2103744 |
| D00842 |
| Depodur (TN) |
| Di(morphine) dihydrogen sulfate pentahydrate |
| DSSTox_CID_28840 |
| DSSTox_GSID_48914 |
| DSSTox_RID_83109 |
| DTXSID1048914 |
| DTXSID4023830 |
| Duramorph |
| Duramorph PF |
| DY70C97N30 |
| EINECS 200-582-8 |
| Kadian (TN) |
| Kapanol |
| l-Morphine sulfate |
| Morphabond |
| Morphinan-3,6-alpha-diol, 7,8-didehydro-4, 5-alpha-epoxy-17-methyl-, sulfate |
| Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5alpha,6alpha)-, sulfate (2:1) (salt) |
| Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-(5-alpha,6-alpha)-, sulfate (2:1) (salt), pentahdrate |
| Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl, (5alpha,6alpha)-, sulfate (2:1) (salt), pentahydrate |
| Morphinan-3,6alpha-diol, 7,8-didehydro-4,5alpha-epoxy-17-methyl-, sulfate (2:1) (salt) |
| Morphinan-3,6alpha-diol, 7,8-didehydro-4,5lpha-epoxy-17-methyl-, sulfate (2:1) (salt), pentahydrate |
| Morphine Extra-Forte |
| Morphine for system suitability, European Pharmacopoeia (EP) Reference Standard |
| Morphine Forte |
| Morphine H.P |
| Morphine hemi[sulfate pentahydrate] |
| Morphine Hemisulfate Pentahemihydrate |
| Morphine Hemisulphate Pentahemihydrate |
| Morphine sulfat, European Pharmacopoeia (EP) Reference Standard |
| MORPHINE SULFATE |
| Morphine Sulfate (anhydrous) |
| Morphine sulfate (USP) |
| Morphine sulfate [USP:JAN] |
| Morphine sulfate hydrate |
| Morphine sulfate hydrate (JP17) |
| MORPHINE SULFATE NARCOTIC ANALGESIC |
| Morphine sulfate pentahydrate |
| Morphine sulfate salt pentahydrate |
| Morphine sulfate salt pentahydrate, analytical standard |
| Morphine sulfate salt solution |
| Morphine sulfate salt solution, 1.0 mg/mL in methanol, drug standard |
| morphine sulfate--dea schedule ii item |
| Morphine sulfate, United States Pharmacopeia (USP) Reference Standard |
| Morphine sulphate |
| Morphine sulphate (2:1) |
| Morphine sulphate pentahydrate |
| Morphine, hemisulfate |
| MORPHINIUMCHLORIDE |
| MS contin (TN) |
| MST-1 Continus |
| NCGC00247707-01 |
| NIH 0001 |
| NIH 10753 |
| NSC 11441 |
| Oramorph SR |
| SCHEMBL29316 |
| Skenan |
| Tox21_112861 |
| UNII-DY70C97N30 |
| UNII-X3P646A2J0 |
| X3P646A2J0 |
US Patents and Regulatory Information for MORPHABOND ER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-001 | Oct 2, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Daiichi Sankyo Inc | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-004 | Oct 2, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Daiichi Sankyo Inc | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-002 | Oct 2, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Daiichi Sankyo Inc | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-004 | Oct 2, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
